View Older Stories View More Recent Stories

Nov 15, 2017 07:05AM Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update
Nov 2, 2017 08:05AM Xenetic Biosciences Enters Into Sublicense Agreement Related to its PolyXen™ Technology with Baxalta Inc., a Wholly-owned Subsidiary of Shire plc
Oct 31, 2017 09:06AM Xenetic Biosciences (XBIO) Appoints Jeffrey Eisenberg as CEO
Oct 31, 2017 09:05AM Xenetic Biosciences Appoints Jeffrey F. Eisenberg as Chief Executive Officer
Oct 2, 2017 10:45AM Xenetic Biosciences Provides Update on Annual Meeting of Stockholders
Aug 23, 2017 08:05AM Xenetic Biosciences Announces Dismissal of Annual Meeting of Stockholders
Aug 15, 2017 08:05AM Xenetic Biosciences Reports 2017 Second Quarter Financial Results and Provides Business Update
Aug 14, 2017 05:00PM Xenetic Biosciences (XBIO) Announces Appointment of Three Directors to the Board
Aug 14, 2017 05:00PM Xenetic Biosciences Announces Appointment of Three Directors to the Board
Jul 18, 2017 04:05PM Xenetic Biosciences Announces Adjournment of Annual Meeting of Stockholders until Wednesday, August 16, 2017
Jun 26, 2017 08:41AM Xenetic Biosciences (XBIO) Begins Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy
Jun 26, 2017 08:35AM Xenetic Biosciences Commences Patient Enrollment in Phase 2 Study Evaluating XBIO-101 in Conjunction with Progestin Therapy for the Treatment of Endometrial Cancer
May 22, 2017 07:05AM Xenetic Biosciences (XBIO) Says Partner Shire (SHPG) Reports Positive Phase 1/2 Study Evaluating SHP656 to Treat Hemophilia A
May 22, 2017 07:00AM Xenetic Biosciences Receives Program Update from Partner Shire’s Phase 1/2 Study Evaluating SHP656 in Development as a Long-acting Treatment for Hemophilia A
May 16, 2017 07:00AM Xenetic Biosciences Reports 2017 First Quarter Financial Results and Provides Business Update
May 9, 2017 08:35AM Xenetic Biosciences to Host 2017 First Quarter Update Conference Call
May 1, 2017 08:30AM Xenetic Biosciences Presents Case Study of PolyXen™ Platform Technology at the 13th Annual Protein Engineering Summit (PEGS) Boston
Apr 20, 2017 07:35AM Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston
Apr 4, 2017 07:07AM Xenetic Biosciences (XBIO) Names James F. Parslow as CFO
Apr 4, 2017 07:05AM Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
Apr 3, 2017 07:35AM Xenetic Biosciences Reports 2016 Year End Financial Results and Provides Business Update
Mar 29, 2017 10:56AM Xenetic Biosciences, Inc. (Nasdaq: XBIO) to Ring The Nasdaq Stock Market Opening Bell
Mar 29, 2017 07:35AM Xenetic Biosciences to Ring Nasdaq Stock Market Opening Bell on March 30, 2017
Mar 27, 2017 08:05AM Xenetic Biosciences Provides Update on Patent Portfolio Development
Mar 9, 2017 08:00AM Xenetic Biosciences to Present at the 29th Annual ROTH Conference
Jan 6, 2017 07:08AM Xenetic Biosciences (XBIO) Receives $3 Million Milestone Payment from Shire (SHPG)
Jan 6, 2017 07:05AM Xenetic Biosciences Receives $3 Million Milestone Payment from Shire plc for PSA-Recombinant SHP656 in Development for Long-Acting Treatment for Hemophilia
Jan 4, 2017 07:35AM Xenetic Biosciences (XBIO) Names Curtis Lockshin as CSO
Jan 4, 2017 07:35AM Xenetic Biosciences Appoints Curtis A. Lockshin, Ph.D. as Chief Scientific Officer
Jan 3, 2017 07:35AM Xenetic Biosciences to Present at Biotech Showcase 2017
Dec 5, 2016 07:05AM Xenetic Biosciences Expands Management Team with Key Appointment of Jeffrey F. Eisenberg as Chief Operating Officer
Dec 1, 2016 07:35AM Xenetic Biosciences to Present at the LD Micro 2016 Annual Conference
Nov 23, 2016 07:05AM Xenetic Biosciences to Host Quarterly Update Conference Call and Webcast
Nov 22, 2016 07:38AM Xenetic Biosciences (XBIO) Names Former Dana-Farber CEO Benz as Director
Nov 22, 2016 07:35AM Xenetic Biosciences Appoints Edward J. Benz, Jr., M.D., Former Dana-Farber CEO, to its Board of Directors
Nov 15, 2016 09:20AM Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update
Oct 10, 2016 07:37AM Xenetic Biosciences (XBIO) Announces Favorable Data from Third Cohort of ErepoXen Phase 3 in Anemia
Oct 10, 2016 07:35AM Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia
Sep 22, 2016 07:05AM Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Aug 19, 2016 12:44PM Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer
Aug 18, 2016 07:00AM Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine
Jul 11, 2016 08:00AM Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors
Jun 1, 2016 07:32AM Xenetic Biosciences, Inc. (XBIO) Board Approves 1-for-33 Reverse Stock Split Ahead of NASDAQ Uplisting
Jun 1, 2016 07:30AM Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market
Apr 1, 2016 08:14AM PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys(TM) for Multiple Sclerosis
Feb 29, 2016 10:32AM Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors
Feb 12, 2016 09:31AM OPKO (OPK) Takes Minority Stake in Xenetic Biosciences
Feb 12, 2016 09:30AM OPKO Health Acquires Interest in Xenetic
Nov 16, 2015 12:09PM Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa™
Oct 7, 2015 07:04AM Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements
View More Recent Stories View Older Stories